-
公开(公告)号：EP2968458A1
公开(公告)日：2016-01-20
申请号：EP14763641.9
申请日：2014-03-14
CPC分类号： A61K38/2242 , A61K9/0019 , A61K38/16 , A61M5/16804 , A61M2005/14208
摘要： Disclosed herein is the use of an active agent comprising a peptide derived from atrial natriuretic peptide (ANP) prohormone or a mimetic thereof in the manufacture of a medicament for treating a disease in a subject. The medicament is administered subcutaneously in a multimodal dosage regime comprising at least an initial dosage stage and at least one maintenance dosage stage. The initial dosage stage comprises infusing the active agent at an initial dosage rate for an initial period to achieve a target steady state blood plasma concentration of the active agent or metabolite thereof. The maintenance dosage stage(s) comprise(s) adjusting the dosage rate to a maintenance dosage rate for a maintenance period to substantially maintain said target steady state blood plasma concentration of the active agent or metabolite thereof.
摘要翻译： 本文公开了包含源自心房利钠肽（ANP）激素原或其模拟物的肽的活性剂在制备用于治疗受试者中的疾病的药物中的用途。 皮下以包含至少初始剂量阶段和至少一个维持剂量阶段的多模式剂量方案施用药物。 初始剂量阶段包括以初始剂量率将活性剂注入初始阶段以实现活性剂或其代谢物的目标稳态血浆浓度。 维持剂量阶段包括将维持剂量率调整为维持剂量率维持一段时间以基本上维持活性剂或其代谢物的所述目标稳态血浆浓度。
-
2.发明授权
公开(公告)号：EP2678025B1
公开(公告)日：2017-03-08
申请号：EP11815913.6
申请日：2011-08-11
CPC分类号： A61K38/1709 , A61K38/2242
-
公开(公告)号：EP2839010A4
公开(公告)日：2015-12-09
申请号：EP13765199
申请日：2013-03-19
发明人： BASTIRAS STAN , GUIDOLIN ANGELO , HUNT BEN , RAISHEED SAIF , ZAREIE REZA
IPC分类号： C12N15/63 , C07K14/575 , C07K19/00 , C12N15/62 , C12N15/70
CPC分类号： C07K14/575 , C07K2319/00 , C07K2319/50 , C12N15/62 , C12P21/06
摘要： Methods of producing a recombinant peptide, such as vessel dilator peptide (VSDL), are disclosed, including a particular method involving expressing a fusion polypeptide comprising concatemeric repeats of the peptide wherein the peptide is flanked by peptide cleavage sites, and cleaving the fusion polypeptide at the peptide cleavage sites with a cleaving agent(s) so as to release the peptide from the fusion polypeptide. Expression constructs and host cells for producing the fusion polypeptide and purification methods for the recombinant peptide are also disclosed.
摘要翻译： 公开了生产重组肽如血管扩张肽（VSDL）的方法，包括涉及表达融合多肽的特定方法，所述融合多肽包含所述肽的连续重复序列，其中所述肽侧翼为肽切割位点，并将所述融合多肽切割 具有切割剂的肽切割位点，以便从融合多肽释放肽。 还公开了用于产生融合多肽的表达构建体和宿主细胞以及重组肽的纯化方法。
-
公开(公告)号：EP2839010B1
公开(公告)日：2018-04-25
申请号：EP13765199.8
申请日：2013-03-19
发明人： BASTIRAS, Stan , GUIDOLIN, Angelo , HUNT, Ben , RAISHEED, Saif , ZAREIE, Reza
IPC分类号： C12P21/06 , C12N15/62 , C07K14/575
CPC分类号： C07K14/575 , C07K2319/00 , C07K2319/50 , C12N15/62 , C12P21/06
摘要： Methods of producing a recombinant peptide, such as vessel dilator peptide (VSDL), are disclosed, including a particular method involving expressing a fusion polypeptide comprising concatemeric repeats of the peptide wherein the peptide is flanked by peptide cleavage sites, and cleaving the fusion polypeptide at the peptide cleavage sites with a cleaving agent(s) so as to release the peptide from the fusion polypeptide. Expression constructs and host cells for producing the fusion polypeptide and purification methods for the recombinant peptide are also disclosed.
-
5.发明公开ADJUVANT THERAPY TO STANDARD OF CARE (SOC) DIURETIC TREATMENT 审中-公开ADJUVANZTHERAPIEFÜRBEHANDLUNGSSTANDARD（SOC）DER DIURETISCHEN BEHANDLUNG
公开(公告)号：EP3116528A1
公开(公告)日：2017-01-18
申请号：EP15761744.0
申请日：2015-03-13
IPC分类号： A61K38/17 , A61K38/22 , A61K31/585 , A61K31/341 , A61P7/10 , A61P9/08 , A61P9/10 , A61P13/12 , A61P9/04
CPC分类号： A61K31/635 , A61K31/197 , A61K31/341 , A61K31/585 , A61K38/2221 , A61K38/2242 , A61K45/06 , A61P9/08 , A61P13/12 , C07K14/58 , A61K2300/00
摘要： A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (VSDL) or a variant or modified peptide thereof. The administration of the diuretic agent may be a component of a standard of care (SOC) treatment.
摘要翻译： 用于治疗和/或预防通常通过施用利尿剂（例如充血性心力衰竭）治疗的疾病和医学病症的治疗方法。 该方法可以包括例如向受试者施用与血管扩张剂（VSDL）或其变体或修饰的肽组合的利尿剂。 利尿剂的给药可以是护理标准（SOC）治疗的组成部分。
-
6.发明公开THERAPEUTIC METHOD FOR TREATING CONGESTIVE HEART FAILURE 有权VSDL ZUR BEHANDLUNG VON AKUTER DEKOMPENSIERTER HERZINSUFFIZIENZ
公开(公告)号：EP2678025A1
公开(公告)日：2014-01-01
申请号：EP11815913.6
申请日：2011-08-11
CPC分类号： A61K38/1709 , A61K38/2242
摘要： The present invention relates to a method of treating congestive heart failure (CHF) in a subject comprising administering a peptide derived from atrial natriuretic peptide (ANP) prohormone (eg vessel dilator; VSDL) or a mimetic thereof. In a particular application, the invention provides a method of treating the particular indication known as acute decompensated congestive heart failure (ADCHF). Devices for intravenous or subcutaneous infusion for use in the method of the invention are also disclosed.
摘要翻译： 本发明涉及一种治疗受试者的充血性心力衰竭（CHF）的方法，包括给予源自心房利尿钠肽（ANP）激素原（例如血管扩张剂; VSDL）或其模拟物的肽。 在特定应用中，本发明提供了治疗被称为急性失代偿性充血性心力衰竭（ADCHF）的特定指征的方法。 还公开了用于本发明方法的用于静脉内或皮下输注的装置。
-
公开(公告)号：EP3116528A4
公开(公告)日：2017-11-29
申请号：EP15761744
申请日：2015-03-13
发明人： GEIMER THOMAS ROBERT
IPC分类号： A61K38/17 , A61K31/341 , A61K31/585 , A61K38/22 , A61P7/10 , A61P9/04 , A61P9/08 , A61P9/10 , A61P13/12
CPC分类号： A61K31/635 , A61K31/197 , A61K31/585 , A61K38/2221 , A61K38/2242 , A61K45/06 , A61K2300/00
摘要： A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (VSDL) or a variant or modified peptide thereof. The administration of the diuretic agent may be a component of a standard of care (SOC) treatment.
-
公开(公告)号：EP2839010A1
公开(公告)日：2015-02-25
申请号：EP13765199.8
申请日：2013-03-19
发明人： BASTIRAS, Stan , GUIDOLIN, Angelo , HUNT, Ben , RAISHEED, Saif , ZAREIE, Reza
CPC分类号： C07K14/575 , C07K2319/00 , C07K2319/50 , C12N15/62 , C12P21/06
摘要： Methods of producing a recombinant peptide, such as vessel dilator peptide (VSDL), are disclosed, including a particular method involving expressing a fusion polypeptide comprising concatemeric repeats of the peptide wherein the peptide is flanked by peptide cleavage sites, and cleaving the fusion polypeptide at the peptide cleavage sites with a cleaving agent(s) so as to release the peptide from the fusion polypeptide. Expression constructs and host cells for producing the fusion polypeptide and purification methods for the recombinant peptide are also disclosed.
-
公开(公告)号：EP2968458A4
公开(公告)日：2016-08-24
申请号：EP14763641
申请日：2014-03-14
CPC分类号： A61K38/2242 , A61K9/0019 , A61K38/16 , A61M5/16804 , A61M2005/14208
摘要： Disclosed herein is the use of an active agent comprising a peptide derived from atrial natriuretic peptide (ANP) prohormone or a mimetic thereof in the manufacture of a medicament for treating a disease in a subject. The medicament is administered subcutaneously in a multimodal dosage regime comprising at least an initial dosage stage and at least one maintenance dosage stage. The initial dosage stage comprises infusing the active agent at an initial dosage rate for an initial period to achieve a target steady state blood plasma concentration of the active agent or metabolite thereof. The maintenance dosage stage(s) comprise(s) adjusting the dosage rate to a maintenance dosage rate for a maintenance period to substantially maintain said target steady state blood plasma concentration of the active agent or metabolite thereof.
-
10.发明公开THERAPEUTIC METHOD FOR TREATING CONGESTIVE HEART FAILURE 有权治疗师VERFAHREN ZUR BEHANDLUNG VON KONGESTIVER HERZINSUFFIZIENZ
公开(公告)号：EP2678025A4
公开(公告)日：2014-07-23
申请号：EP11815913
申请日：2011-08-11
发明人： GEIMER ROBERT THOMAS
CPC分类号： A61K38/1709 , A61K38/2242
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.012 秒)
